BridgeBio Pharma Enters Seven Collaborations with University Partners

Rare Daily Staff

BridgeBio Pharma announced seven separate collaborations with top academic and research institutions to support early, promising research in genetically driven diseases and cancers with clear genetic drivers.

BridgeBio announced partnerships with Brown University, GlycoNet, The Lundquist Institute, Oregon Health & Science University, Roswell Park Comprehensive Cancer Center, the University of California, San Diego; and University of California, Davis.

The latest set of deals brings the total number of partnerships between BridgeBio and leading academic and research institutions to 20 to date.

Through the partnerships BridgeBio will:

• Collaborate with UC San Diego on identifying research programs with strong potential for therapeutic applications that address areas of unmet need. BridgeBio will potentially sponsor research programs and support the development of identified programs toward potential clinical investigation through its licensing and affiliate development model.
  
  
• Work with scientists at Roswell Park Comprehensive Cancer Center to evaluate new research and development opportunities in oncology that have promise to advance and potentially provide clinical benefit for patients. Select therapeutic programs may be pursued by BridgeBio, in close collaboration with Roswell Park Comprehensive Cancer Center scientists, who would remain deeply involved in the ongoing development of these investigational therapies.
  
  
• Build on five years of informal collaboration with Oregon Health & Science University in Portland, Oregonto advance research and the development of investigational medicines for patients with genetically driven conditions. Under the agreement, the BridgeBio team will work closely with OHSU scientists and investigators to advance potential medicines for patients with genetically driven conditions, including cancers.
  
  
• Work with The Lundquist Institute for Biomedical Innovation at the Harbor-UCLA Medical Center to translate research in genetically driven diseases and cancers into potential treatments for patients. Under the established two-year partnership, BridgeBio will work closely with The Lundquist Institute researchers to identify programs that may have the potential to become therapies for patients with genetically driven conditions and cancers. BridgeBio will potentially sponsor research programs and support the development of Lundquist programs and clinical investigations through its licensing and affiliate development model.
  
  
• Work alongside the Canadian Glycomics Network (GlycoNet), a pan-Canadian Network of Centers of Excellence, under a collaboration to identify research programs that may have the potential to become treatments for genetic diseases. BridgeBio will potentially sponsor research programs and support clinical investigation through its licensing and affiliate development model. Genetic disease research has benefitted substantially from the study of glycomics, which relates to the functions of glycans, or sugar, in biological systems.
  
  
• And collaborate with scientists at Brown to evaluate new discoveries in neurology research that have promise to advance toward clinical investigation. Select therapeutic programs may be spun out and advanced in BridgeBio affiliate companies, with an opportunity for Brown University scientists to support as company leaders and guide ongoing development.

Photo: BridgeBio CEO Neil Kumar